Cargando…

Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?

Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trails. In the future, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, R. H., Houston, R. F., Moorehead, R. J.
Formato: Texto
Lenguaje:English
Publicado: Ulster Medical Society 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2449093/
https://www.ncbi.nlm.nih.gov/pubmed/8658995
_version_ 1782157294529675264
author Wilson, R. H.
Houston, R. F.
Moorehead, R. J.
author_facet Wilson, R. H.
Houston, R. F.
Moorehead, R. J.
author_sort Wilson, R. H.
collection PubMed
description Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trails. In the future, immunotherapy and gene therapy may be of benefit but these are still many years from the clinical arena. We believe that current evidence suggests that patients with Dukes B and C colorectal cancer should be entered into trials of adjuvant therapy. This evidence is reviewed below among with estimates of the impact that adjuvant therapy would have on the outcome from this disease in Northern Ireland.
format Text
id pubmed-2449093
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Ulster Medical Society
record_format MEDLINE/PubMed
spelling pubmed-24490932008-07-10 Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? Wilson, R. H. Houston, R. F. Moorehead, R. J. Ulster Med J Research Article Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trails. In the future, immunotherapy and gene therapy may be of benefit but these are still many years from the clinical arena. We believe that current evidence suggests that patients with Dukes B and C colorectal cancer should be entered into trials of adjuvant therapy. This evidence is reviewed below among with estimates of the impact that adjuvant therapy would have on the outcome from this disease in Northern Ireland. Ulster Medical Society 1994-04 /pmc/articles/PMC2449093/ /pubmed/8658995 Text en
spellingShingle Research Article
Wilson, R. H.
Houston, R. F.
Moorehead, R. J.
Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title_full Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title_fullStr Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title_full_unstemmed Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title_short Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
title_sort adjuvant therapy for colorectal cancer--is there a place for a northern ireland study?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2449093/
https://www.ncbi.nlm.nih.gov/pubmed/8658995
work_keys_str_mv AT wilsonrh adjuvanttherapyforcolorectalcanceristhereaplaceforanorthernirelandstudy
AT houstonrf adjuvanttherapyforcolorectalcanceristhereaplaceforanorthernirelandstudy
AT mooreheadrj adjuvanttherapyforcolorectalcanceristhereaplaceforanorthernirelandstudy